Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	31.11	30.28	21.59	0	-29.13
Depreciation & Amortization	10.94	11.52	11.52	9.84	11.31
Stock-Based Compensation	6.94	8.25	10.25	11.83	32.63
Other Adjustments	-0.36	-0.52	1.51	7	7.15
Change in Receivables	-21.28	16.35	-8.37	-7.82	-5.98
Changes in Inventories	3.21	-1.64	-2.55	2.58	-3.66
Changes in Accounts Payable	-0.45	-1.38	0.45	-4.73	-0.9
Changes in Accrued Expenses	13.15	-15.82	-7.58	-33.07	5.21
Changes in Other Operating Activities	-1.46	-8.11	0.2	-1.46	4.02
Operating Cash Flow	41.8	38.92	27.01	-15.83	20.65
Operating Cash Flow Growth	7.41%	44.09%	-	-	2571.41%
Capital Expenditures	-0.07	-0.06	-0.14	-	-
Purchases of Intangible Assets	-	-	-12.5	-7	-
Purchases of Investments	-108.14	-76.23	-23.81	-4.84	-38.07
Proceeds from Sale of Investments	72.02	55.85	17.33	18.94	27.19
Investing Cash Flow	-36.19	-20.44	-19.13	7.1	-10.88
Long-Term Debt Issued	-	-	-	-	98.5
Long-Term Debt Repaid	-44.44	-33.33	-	-	-100
Net Long-Term Debt Issued (Repaid)	-44.44	-33.33	-	-	-1.5
Issuance of Common Stock	0.13	0.15	-	12.5	-
Net Common Stock Issued (Repurchased)	0.13	0.15	-	12.5	-
Other Financing Activities	-0.89	-0.67	-	-0.28	-30.43
Financing Cash Flow	-45.2	-33.85	-	12.22	-31.93
Net Cash Flow	-39.58	-15.37	7.88	3.5	-22.16
Free Cash Flow	41.73	38.86	26.87	-15.83	20.65
Free Cash Flow Growth	7.38%	44.64%	-	-	2740.44%
FCF Margin	18.27%	16.86%	11.40%	-6.94%	8.16%
Free Cash Flow Per Share	0.82	0.79	0.57	-0.35	0.51
Levered Free Cash Flow	11.99	-18.54	23.48	-26.83	-14.65
Unlevered Free Cash Flow	57.74	23.42	32.97	-26.73	17.28

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q